Why the Lifehealthcare Group Ltd share price is surging today

Here's what you need to know about Lifehealthcare Group Ltd's (ASX:LHC) full-year results.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a poorer-than-expected half-year that saw shares crushed earlier this year, Lifehealthcare Group Ltd (ASX: LHC) has reported its full year results to the market this morning. Although a strong headline result, the underlying performance of Lifehealthcare was mixed.

Here's what you need to know:

  • Revenues rose 16% to $115 million
  • Net Profit After Tax ("NPAT") rose 102% to $7.5 million
  • Underlying NPATA* rose 1.4% to $8.8 million
  • Diluted Earnings Per Share of 17 cents per share
  • Dividends per share of 12.5 cents per share
  • Margins declined 0.6% due to changing product mix and weaker Australian Dollar
  • Outlook for mid-single digit revenue growth, with low to mid-single digit EBITDA growth due to weaker AUD impact

*NPAT excluding impact of intangibles, one-offs, and in this case a $4.5 million tax penalty incurred in the previous year

So What?

Well, the headwinds that afflicted the company have stuck around for the full year. Lower margins due to a weaker Australian Dollar (since Lifehealthcare sources its product from overseas) were well flagged but in this case partially insulated by the group's hedging strategy. Management has guided for more margin deterioration in 2017 as the group's inventory is replaced and hedging strategies roll over.

As a result of a $4.5 million tax payment incurred in 2015 (which dragged that year's results down), profits this year appear to have doubled due to not having to make that payment again. For this reason, using the underlying NPATA figure, which was up just 1.4%, is more appropriate.

On the operational front it was good to see that the group's cash performance got back on track with the company generating an operating cash surplus after the deficit in the first half. A stronger second half following new product releases saw working capital (as a percentage of revenue) return to more normal levels of 31%, down from 35%.

Prosthetics pricing effects

So far, concerns over changes to prosthetics pricing have proven to be a storm in a teacup. Lifehealthcare also reports it has no exposure to areas that are initially coming under focus for review by the Industry Working Group. However, 38% of revenues are drawn from 'Prosthesis List' (implants which get reimbursed by insurers) and this remains a risk area even if the likelihood of impact appears to have decreased.

Big tailwinds from an ageing population?

Like Healthscope Ltd (ASX: HSO), Lifehealthcare uses Australian Bureau of Statistics (ABS) projections of an ageing population to suggest a long-term tailwind for product demand. The portion of the population over 85 is expected to increase from 15% currently to 19% by 2030, with a corresponding impact on demand for healthcare services. As a junior healthcare company however, investors should remember Lifehealthcare's future is far more dependent on its operating performance now rather than long-term tailwinds.

Now What?

Although the results for the year weren't stellar, they weren't too bad and considering the group's relatively low price tag, I expect shares could rise today. A drawback for me was that strong revenue growth was held back by an increase in depreciation and amortisation, the former of which was due to 'increased instrument kit investments across FY15 and FY16, supporting revenue growth' which suggests that at least in part, higher depreciation expenses might be repeated in future years.

An increase in new surgeon numbers was a big positive and should help drive sales forward next year. The outlook for 2017 is for limited growth but at today's price of 9 times underlying profit I think many of the risks are priced in to Lifehealthcare.

Motley Fool contributor Sean O'Neill owns shares of LifeHealthcare Group Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »